We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

143 hedge funds and large institutions have $571M invested in Array Biopharma Inc in 2013 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 42 increasing their positions, 50 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

7% more funds holding

Funds holding: 134 → 143 (+9)

12% less capital invested

Capital invested by funds: $651M → $571M (-$79.8M)

16% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 50

83% less call options, than puts

Call options by funds: $771K | Put options by funds: $4.48M

Holders
143
Holders Change
+9
Holders Change %
+6.72%
% of All Funds
4.15%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.17%
New
27
Increased
42
Reduced
50
Closed
17
Calls
$771K
Puts
$4.48M
Net Calls
-$3.71M
Net Calls Change
-$2.71M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.5M
2
TCM
TimesSquare Capital Management
New York
+$13.7M
3
RG
Redmile Group
California
+$4.31M
4
DM
Deerfield Management
New York
+$3.54M
5
PA
Pinnacle Associates
New York
+$3.37M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$11.8M
2
GC
GMT Capital
Georgia
-$9.85M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$8.39M
4
PI
Putnam Investments
Massachusetts
-$3.73M
5
PA
Perceptive Advisors
New York
-$3.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
FLAM
26
First Light Asset Management
Minnesota
$4.31M +$4.68M +860,066 New
Principal Financial Group
27
Principal Financial Group
Iowa
$4.28M -$2.84M -521,108 -38%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.09M +$35.3K +6,479 +1%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$2.66M +$62K +11,389 +2%
GC
30
GMT Capital
Georgia
$2.52M -$9.85M -1,808,559 -78%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$2.49M +$1.98M +364,438 +277%
GC
32
Guggenheim Capital
Illinois
$2.42M +$294K +54,043 +13%
TCIM
33
TIAA CREF Investment Management
New York
$2.4M +$37.2K +6,841 +1%
CGT
34
Capital Guardian Trust
California
$2.38M – – –
SCM
35
Suffolk Capital Management
New York
$2.33M +$524K +96,200 +26%
BG
36
BlackRock Group
United Kingdom
$2.18M +$110K +20,243 +5%
Renaissance Technologies
37
Renaissance Technologies
New York
$1.82M -$1.21M -222,900 -38%
RPAM
38
Rhenman & Partners Asset Management
Sweden
$1.8M +$1.96M +360,000 New
BIM
39
BlackRock Investment Management
Delaware
$1.69M +$37K +6,800 +2%
TD Asset Management
40
TD Asset Management
Ontario, Canada
$1.67M +$34.3K +6,300 +2%
TC
41
TFS Capital
Pennsylvania
$1.6M -$2.14M -393,061 -55%
BlackRock
42
BlackRock
New York
$1.58M +$1.69M +311,312 +8,414%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$1.53M -$28.1K -5,160 -2%
NI
44
Numeric Investors
Massachusetts
$1.48M -$680K -124,986 -30%
PAM
45
Panagora Asset Management
Massachusetts
$1.43M -$64.6K -11,864 -4%
Charles Schwab
46
Charles Schwab
California
$1.4M +$48.2K +8,862 +3%
SONJCPFA
47
State of New Jersey Common Pension Fund A
New Jersey
$1.33M – – –
CS
48
Credit Suisse
Switzerland
$1.28M +$801K +147,117 +136%
ARTA
49
A.R.T. Advisors
New York
$1.27M +$11.6K +2,134 +0.8%
Allianz Asset Management
50
Allianz Asset Management
Germany
$1.26M -$81.8K -15,029 -6%
1
2
3 4 5

ARRY Hedge Fund Activity: Q4 2013 in Review

143 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2013, worth a combined $571M — down 12% from $651M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ARRY positions and 17 closed out — a net gain of 10 holders — while 42 added to existing stakes and 50 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $43.5M. The largest seller was BVF Inc, cutting an estimated $11.8M.

  • 143 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2013, up from 134 in Q3 2013.
  • Funds reported $571M of Array Biopharma Inc stock for Q4 2013, down 12% quarter-over-quarter.
  • 27 funds opened new Array Biopharma Inc positions in Q4 2013 and 17 closed out, a net change of +10 holders.
  • The largest Array Biopharma Inc buyer in Q4 2013 was Fidelity Investments, an estimated $43.5M added.
  • The largest Array Biopharma Inc seller in Q4 2013 was BVF Inc, an estimated $11.8M sold.

Based on aggregated 13F filings for Q4 2013.